FCF Biotech
Public Equity Monitor
The Biotech Public Equity Monitor is the most detailed and comprehensive valuation analysis for biotechnology and pharmaceutical companies in the micro, small and midcap market segment in Europe. Categorized by subsectors / indications, it provides relevant valuation metrics (e.g. ratios, multiples), general information, performance data, analyst consensus and shareholder analysis as well as statistics by region and subsector / indication.
FCF Biotech Public Equity Monitor
Share Price Potential...
Performance and Valuation..
Break-Even Analysis...
Liquidity Analysis...
Shareholder Analysis...
Previous
Next

As of the end of November 2021, we identify the following trends in Europe:

  • The overall price development of the European therapeutics sector rose by an average of +20% last year
  • Within the Therapeutics Sector, the Infectious Diseases sector recorded the highest share price performance within the last year with +125%, followed by Ophthalmology (+109%) and Respiratory (+52%)
  • Analysts see an average upside potential of +130% in the share prices of the European Therapeutics Sector
FCF Biotech Public Equity Monitor
Share Price Potential...
Performance and Valuation..
Break-Even Analysis...
Liquidity Analysis...
Shareholder Analysis...
Previous
Next

Capital Markets Research

We constantly engage in capital markets research to identify financing trends early in the Life Sciences sector. Our research focuses on the most relevant equity markets: Venture Capital, Public Equity, Initial Public Offerings (IPO). The findings are currently published in the following publications:

NEWS

Psychedelics attract more VC investments

Investment into US and European psychedelics companies have been continuously increasing over the past years as mental health gains in importance. Whereas only 12 venture capital transactions were conducted in 2016, the number of transactions

Read more »